PortfoliosLab logoPortfoliosLab logo
ATAI vs. IOVA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ATAI vs. IOVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ATAI achieves a -0.98% return, which is significantly lower than IOVA's 48.72% return.


ATAI

1D
-0.25%
1M
-6.25%
YTD
-0.98%
6M
-5.81%
1Y
63.31%
3Y*
37.73%
5Y*
-26.10%
10Y*

IOVA

1D
3.84%
1M
-1.22%
YTD
48.72%
6M
46.04%
1Y
105.05%
3Y*
-20.47%
5Y*
-30.33%
10Y*
-6.39%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ATAI vs. IOVA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ATAI
Atai Life Sciences N.V.
-0.98%207.52%-5.67%-46.99%-65.14%-63.67%
IOVA
Iovance Biotherapeutics, Inc.
48.72%-63.11%-8.98%27.23%-66.53%-22.46%

Correlation

The correlation between ATAI and IOVA is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.27

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.39

Correlation (All Time)
Calculated using the full available price history since Jun 18, 2021

0.39

The correlation between ATAI and IOVA shifts across timeframes, from 0.27 (1 year) to 0.39 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ATAI:

$1.45B

IOVA:

$1.70B

EPS

ATAI:

-$2.67

IOVA:

-$0.93

PS Ratio

ATAI:

288.44

IOVA:

5.42

PB Ratio

ATAI:

7.29

IOVA:

2.35

Total Revenue (TTM)

ATAI:

$3.49M

IOVA:

$285.61M

Gross Profit (TTM)

ATAI:

$3.49M

IOVA:

$327.04M

EBITDA (TTM)

ATAI:

-$663.38M

IOVA:

-$325.45M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ATAI vs. IOVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI
ATAI Risk / Return Rank: 6767
Overall Rank
ATAI Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
ATAI Sortino Ratio Rank: 7070
Sortino Ratio Rank
ATAI Omega Ratio Rank: 6969
Omega Ratio Rank
ATAI Calmar Ratio Rank: 6767
Calmar Ratio Rank
ATAI Martin Ratio Rank: 6262
Martin Ratio Rank

IOVA
IOVA Risk / Return Rank: 7474
Overall Rank
IOVA Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
IOVA Sortino Ratio Rank: 7979
Sortino Ratio Rank
IOVA Omega Ratio Rank: 7474
Omega Ratio Rank
IOVA Calmar Ratio Rank: 7575
Calmar Ratio Rank
IOVA Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATAI vs. IOVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ATAIIOVADifference
Sharpe ratioReturn per unit of total volatility

-0.26

Sortino ratioReturn per unit of downside risk

-0.46

Omega ratioGain probability vs. loss probability

1.21

1.24

-0.04

Calmar ratioReturn relative to maximum drawdown

1.32

1.94

-0.62

Martin ratioReturn relative to average drawdown

2.08

3.05

-0.97

ATAI vs. IOVA - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 0.79, which is comparable to the IOVA Sharpe Ratio of 1.04. The chart below compares the historical Sharpe Ratios of ATAI and IOVA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ATAI vs. IOVA - Drawdown Comparison

The maximum ATAI drawdown since its inception was -95.05%, roughly equal to the maximum IOVA drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for ATAI and IOVA.


Loading charts...

Drawdown Indicators


ATAIIOVADifference

Max Drawdown

Largest peak-to-trough decline

-95.05%

-99.37%

+4.32%

Max Drawdown (1Y)

Largest decline over 1 year

-48.06%

-54.41%

+6.35%

Max Drawdown (3Y)

Largest decline over 3 years

-59.23%

-90.50%

+31.27%

Max Drawdown (5Y)

Largest decline over 5 years

-94.66%

-93.99%

-0.67%

Max Drawdown (10Y)

Largest decline over 10 years

-96.84%

Current Drawdown

Current decline from peak

-80.71%

-97.45%

+16.74%

Average Drawdown

Average peak-to-trough decline

-80.78%

-84.18%

+3.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.56%

34.61%

-4.05%

Volatility

ATAI vs. IOVA - Volatility Comparison

The current volatility for Atai Life Sciences N.V. (ATAI) is 20.22%, while Iovance Biotherapeutics, Inc. (IOVA) has a volatility of 25.62%. This indicates that ATAI experiences smaller price fluctuations and is considered to be less risky than IOVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ATAIIOVADifference

Volatility (1M)

Calculated over the trailing 1-month period

20.22%

25.62%

-5.40%

Volatility (6M)

Calculated over the trailing 6-month period

50.35%

64.08%

-13.73%

Volatility (1Y)

Calculated over the trailing 1-year period

81.08%

101.54%

-20.46%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

83.62%

89.88%

-6.26%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.63%

81.44%

+2.19%

Dividends

ATAI vs. IOVA - Dividend Comparison

Neither ATAI nor IOVA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ATAI vs. IOVA - Financials Comparison

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and Iovance Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
954.00K
71.43M
(ATAI) Total Revenue
(IOVA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ATAI and IOVA have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IOVA has higher volatility (25.62%) compared to ATAI (20.22%). In terms of maximum drawdown, ATAI dropped -95.05% vs IOVA's -99.37%.

IOVA currently has the higher Sharpe Ratio (1.04 vs 0.79), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ATAI and IOVA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer